PARIS (Reuters) – The U.S. Food & Drug Administration (FDA) regulatory body has accepted for priority review the use of Sanofi and Regeneron’s Dupixent product for children aged 6-11 with moderate-to-severe eczema, the companies said.
Sanofi and Regeneron added in a statement that if Dupixent won approval from the FDA, it would become the first biologic medicine available in the United States for such children.
The FDA is due to make its decision on May 26.
(Reporting by Sudip Kar-Gupta; Editing by Kim Coghill)
